Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer

Ovarian cancer is the deadliest gynecologic malignancy in industrialized countries [1]. Most women with ovarian cancer are diagnosed at advanced stages and recurrence is common after initial platinum-based chemotherapy leading to incurable disease with limited treatment options [2]. Therefore, a critical need remains for new effective therapeutic strategies.

Source: Cancer Treatment Reviews - April 9, 2020 Category: Cancer & Oncology Authors: Tzu-Ting Huang, Erika J. Lampert, Cynthia Coots, Jung-Min Lee Tags: Anti-tumour Treatment Source Type: research